Loading…
Inovio Pharmaceuticals Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.6% over 5Y.
today you would have $13.73▼ -98.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.74 | $1.83 | $6.12 | $18.72 | |
| P/S | 235.5x | 1837.3x | 303.4x | 167.7x | 38.5x |
| P/B | 1.5x | 5.0x | 1.0x | 1.2x | 1.8x |
| EPS | -$1.81 | -$3.95 | -$6.09 | -$14.04 | |
| Profit margin | -32747.07% | -130000.00% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HURATuHURA Biosciences, Inc. | $2.11 | — | 7.4x | — | -161.39% | $134.46M |
| INGNInogen Inc | $5.09 | — | 0.8x | — | -13.14% | $135.08M |
| IMDXInsight Molecular Diagnostics Inc. | $4.13 | — | — | — | — | $135.15M |
| BGMBGM Group Ltd. | $0.33 |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Company description provided by Yahoo Finance.
| -49254.27% |
| -16239.87% |
| -2726.67% |
| ROE | -141.20% | -352.53% | -156.57% | -115.14% | -125.84% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.2x |
| — |
| -9.27% |
| $131.2M |
| LENZLENZ Therapeutics, Inc. | $4.13 | — | 0.6x | — | -59.21% | $129.77M |
| APYXApyx Medical Corp | $3.08 | — | 12.2x | — | -90.69% | $129.74M |